The global hemostasis products market is estimated to grow at a significant CAGR during the forecast period. The key factor contributing to the growth of the global hemostasis products market includes the rising number of trauma and surgical cases and technological advancements in the market such as modified chitosan dressing, intranasal splint for nasal/sinus surgery, hemostatic foams for the treatment of nosebleed, and many more. Surgical cases are recognized by the World Health Organization (WHO), as inevitable to manage several health conditions, which include CVD, injuries, cancer, obstructed labor, birth defects, and other conditions. According to the Lancet Commission on Global Surgery, Global Surgery 2030, 28-32% of the global burden of disease can be attributed to surgically treatable conditions in 2014 and is expected to increase by 60% in 2030. 

Hemostasis is the process in which bleeding or hemorrhage is stopped from the blood vessels due to normal vasoconstriction, abnormal vasoconstriction or coagulation, or surgical means (ligation), using the combined activity of vascular factors, platelets, and plasma coagulation regulators. For this purpose, the hemostasis products are used as they aid to control bleeding during surgery or accidents or trauma and also acts as fresh frozen plasma. The COVID-19 pandemic affected the hemostasis products market including the drop in the emergency surgical procedures and reduction in the operations, additionally, the reduction in the non-essential surgeries such as plastic surgeries affected the growth of the market. 

The key players contributing to the growth of the global hemostasis products market by adopting various strategies such as product launches and developments, mergers and acquisitions, partnerships, and agreements, include Abbott Laboratories, Baxter International, Inc., C. R. Bard, Inc. (BD), CSL Behring LLC, Dexur, Grifols, S.A., Johnson & Johnson, Medtronic plc, Pfizer, Inc., Tricol Biomedical, among others. For instance, AQUABRI is a surgical sealant for aortic procedures launched by the Terumo Corporation in February 2020. It acts by reacting with water in the plasma and forming an elastic layer that adheres to the tissues. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product

o By Application

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia Pacific

o Rest of the World

• Competitive Landscape- Abbott Laboratories, Baxter International, Inc., C. R. Bard, Inc. (BD), CSL Behring LLC, Dexur, Grifols, S.A., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hemostasis Products Market -segmentation

By Product

• Topical Hemostasis Product 

o Collagen

o Oxidized Regenerated Cellulose

o Gelatin

o Polysaccharides

o Others

• Infusible Hemostasis Product 

o Fresh Frozen Plasma

o Platelet Concentrate from Donor Blood

o Factor VIII

o Prothrombin Complex

o Others

• Advanced Hemostasis Product 

o Flowable Complex

o Thrombin Complex

o Fibrin Complex

o Synthetic Sealants 

o Others

By Application

• Trauma
• Surgery
• Hemophilia
• Myocardial Infarction
• Thrombosis
• Others

By Distribution Channel

• Hospital
• Retail Pharmacy
• Online
• Others

Global Hemostasis Products Market –segmentation by region